| Literature DB >> 30450580 |
Parastoo Shabani1, Sama Izadpanah1, Ali Aghebati-Maleki1,2,3, Elham Baghbani1, Amir Baghbanzadeh1, Ali Fotouhi4, Babak Bakhshinejad5, Leili Aghebati-Maleki1,6, Behzad Baradaran1,6.
Abstract
Osteosarcoma (OS) is the most common primary malignant tumor of the bone with a strong tendency to early metastasis, and occurs in growing bones more commonly in children and adolescents. Considering the limited therapeutic methods and lack of 100% success of these methods, developing innovative therapies with high efficacy and lower side effects is needed. Meanwhile, miRNAs and the studies indicating the involvement of miRNAs in OS development have attracted attentions as a result of the frequent abnormalities in expression of miRNAs in cancer. miRNAs are noncoding short sequences with lengths ranging from 18 to 25 nucleotides that play a very important role in cellular processes, such as proliferation, differentiation, migration, and apoptosis. MiRNAs can have either oncogenic or tumor suppressive role based on cellular function and targets. This review aimed to have overview on miR-142 as a tumor suppressor in OS. Moreover, the genes involved in the disease, such as RAC1, HMAG1, MMP9, MMP2, and E-cadherin, which have irregularities as a result of change in miR-142 expression, and, thereby, result in increasing the proliferation, invasion, and metastasis of the cells in the tissues and OS cells will be discussed.Entities:
Keywords: cancer therapy; microRNA-142; osteosarcoma
Mesh:
Substances:
Year: 2018 PMID: 30450580 DOI: 10.1002/jcb.27857
Source DB: PubMed Journal: J Cell Biochem ISSN: 0730-2312 Impact factor: 4.429